Drug Discovery Weekly — April 14, 2026
This week delivered a string of significant FDA decisions in rare disease, with Travere's Filspari earning the FDA's first-ever approval for focal segmental glomerulosclerosis (FSGS), joining other recent wins in orphan indications. Eli Lilly's Jaypirca scored a Phase 3 CLL trial win demonstrating fixed-duration efficacy, while Regeneron made a bold $2.1B move into radiopharmaceuticals via an Australian partnership with Telix. On the deals front, Garda Therapeutics acquired Assertio and its chemotherapy drug Rolvedon for $125M, and AbbVie escalated its legal battle over the federal 340B drug discount program.
6 min read/15 sources
